BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 33677092)

  • 1. mRNA-encoded, constitutively active STING
    Tse SW; McKinney K; Walker W; Nguyen M; Iacovelli J; Small C; Hopson K; Zaks T; Huang E
    Mol Ther; 2021 Jul; 29(7):2227-2238. PubMed ID: 33677092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
    Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
    Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and treatment of HPV-related cancer through a mRNA vaccine expressing APC-targeting antigen.
    Li X; Wang H; Lai W; Liao J; Mo W; Huang K; He L; Liang X; Yu Z; Xu J; Hua X; Hou F; Ding J; Jia WW; Zhang K; Wang Y
    Immunology; 2024 Jul; 172(3):375-391. PubMed ID: 38471664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.
    Nakagawa T; Tanino T; Onishi M; Tofukuji S; Kanazawa T; Ishioka Y; Itoh T; Kugimiya A; Katayama K; Yamamoto T; Nagira M; Ishii KJ
    Front Immunol; 2021; 12():803090. PubMed ID: 35003132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
    Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
    Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
    Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
    BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant.
    Korsholm KS; Hansen J; Karlsen K; Filskov J; Mikkelsen M; Lindenstrøm T; Schmidt ST; Andersen P; Christensen D
    Vaccine; 2014 Jun; 32(31):3927-35. PubMed ID: 24877765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine.
    Vasievich EA; Chen W; Huang L
    Cancer Immunol Immunother; 2011 May; 60(5):629-38. PubMed ID: 21267720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral delivery of the chitin-derived C100 adjuvant promotes robust STING, IFNAR, and CD8
    Turley JL; Ward RW; Huete-Carrasco J; Muñoz-Wolf N; Roche K; Jin L; Bowie A; Andersson M; Lavelle EC
    Cell Rep Med; 2024 May; 5(5):101560. PubMed ID: 38729159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
    Song MY; Park SH; Nam HJ; Choi DH; Sung YC
    J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
    Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
    J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen Delivery to DEC205
    Silva MO; Almeida BS; Sales NS; Diniz MO; Aps LRMM; Rodrigues KB; Silva JR; Moreno ACR; Porchia BFMM; Sulczewski FB; Boscardin SB; Ferreira LCS
    Int J Biol Sci; 2021; 17(11):2944-2956. PubMed ID: 34345218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
    Peng S; Tan M; Li YD; Cheng MA; Farmer E; Ferrall L; Gaillard S; Roden RBS; Hung CF; Wu TC
    Cancer Immunol Immunother; 2021 Apr; 70(4):1049-1062. PubMed ID: 33108473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice.
    Hansen J; Lindenstrøm T; Lindberg-Levin J; Aagaard C; Andersen P; Agger EM
    Cancer Immunol Immunother; 2012 Jun; 61(6):893-903. PubMed ID: 22095092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.
    Lee SY; Kang TH; Knoff J; Huang Z; Soong RS; Alvarez RD; Hung CF; Wu TC
    Cancer Immunol Immunother; 2013 Jul; 62(7):1175-85. PubMed ID: 23615841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand.
    Hung CF; Hsu KF; Cheng WF; Chai CY; He L; Ling M; Wu TC
    Cancer Res; 2001 Feb; 61(3):1080-8. PubMed ID: 11221836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11.
    Namkoong H; Song MY; Seo YB; Choi DH; Kim SW; Im SJ; Sung YC; Park Y
    Vaccine; 2014 Feb; 32(10):1205-12. PubMed ID: 23928465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
    Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
    Front Immunol; 2018; 9():2968. PubMed ID: 30631324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells.
    Kim D; Hung CF; Wu TC; Park YM
    Vaccine; 2010 Oct; 28(45):7297-305. PubMed ID: 20817010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.